VRDN
Viridian Therapeutics, Inc.
$17.24
-0.45
(-2.54%)
Mkt Cap
1.55B
Volume
2,799,250
52W Range
13.18-34.29
Sector
Healthcare
Beta
0.82
EPS (TTM)
-3.48
P/E Ratio
-7.70
Revenue (TTM)
70.92M
Rev Growth (5Y)
+132.2%
EPS Growth (5Y)
N/A
Company Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.85M | 302,000 | 314,000 | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4.00M | 3.34M | 2.54M | 4.32M |
| Net Income | (342.60M) | (269.95M) | (237.73M) | (129.87M) | (79.41M) | (110.72M) | (41.87M) | (32.70M) | (26.51M) | (12.67M) | (11.33M) | (7.89M) |
| EPS | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 | -20.31 | -16.57 | -20.66 | -17.57 | -21.00 | -52.46 |
| Free Cash Flow | (276.89M) | (232.83M) | (185.07M) | (94.64M) | (54.92M) | (29.82M) | (36.14M) | (27.29M) | (28.41M) | (7.23M) | N/A | N/A |
| FCF / Share | -3.27 | -3.43 | -4.14 | -2.95 | -4.61 | -8.38 | -17.30 | -13.83 | -22.15 | -10.03 | N/A | N/A |
| Operating CF | (276.39M) | (232.32M) | (184.17M) | (93.84M) | (54.58M) | (29.78M) | (36.06M) | (26.84M) | (28.17M) | (7.23M) | N/A | N/A |
| Total Assets | 899.42M | 742.40M | 490.42M | 435.09M | 203.71M | 131.25M | 30.26M | 66.15M | 52.48M | 4.26M | N/A | N/A |
| Total Debt | 50.69M | 21.09M | 21.05M | 5.26M | 520,000 | 455,000 | 8.30M | 10.30M | 9.92M | 1.04M | N/A | N/A |
| Cash & Equiv | 212.38M | 99.59M | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M | 32.61M | 47.44M | 3.34M | N/A | N/A |
| Book Value | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | (326,000) | N/A | N/A |
| Return on Equity | -0.47 | -0.40 | -0.54 | -0.33 | -0.42 | -0.92 | -2.66 | -0.64 | -0.69 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 141,000 | 132,000 | 70.57M | 75,000 | 72,000 | 72,000 | 86,000 | 72,000 | 72,000 | 72,000 | 72,000 | 72,000 |
| Net Income | (104.90M) | (120.36M) | (34.60M) | (100.73M) | (86.91M) | (79.72M) | (76.69M) | (64.99M) | (48.54M) | (66.86M) | (47.66M) | (55.06M) |
| EPS | -1.03 | -1.11 | -0.34 | -1.00 | -0.87 | -0.81 | -1.15 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 |
| Free Cash Flow | (119.68M) | (23.99M) | (84.74M) | (75.42M) | (92.74M) | (73.45M) | (68.00M) | (46.16M) | (45.22M) | (38.05M) | (39.39M) | (45.55M) |
| FCF / Share | -1.17 | -0.28 | -1.04 | -0.92 | -1.14 | -0.92 | -1.02 | -0.72 | -0.74 | -0.77 | -0.90 | -1.05 |
| Operating CF | (119.65M) | (23.75M) | (84.61M) | (75.37M) | (92.65M) | (73.33M) | (67.71M) | (46.06M) | (45.22M) | (38.00M) | (38.98M) | (45.21M) |
| Total Assets | 789.02M | 899.42M | 577.14M | 582.32M | 660.98M | 742.40M | 771.90M | 585.66M | 630.38M | 490.42M | 328.76M | 351.47M |
| Total Debt | 51.17M | 50.69M | 23.82M | 21.34M | 21.22M | 21.09M | 21.11M | 20.96M | 21.06M | 21.05M | 20.82M | 5.51M |
| Cash & Equiv | 176.35M | 212.38M | 169.65M | 117.32M | 116.22M | 99.59M | 200.32M | 107.67M | 91.64M | 102.83M | 111.60M | 87.08M |
| Book Value | 636.01M | 722.17M | 502.97M | 515.17M | 604.47M | 671.64M | 707.50M | 529.34M | 582.53M | 442.02M | 283.58M | 315.86M |
| Return on Equity | -0.16 | -0.17 | -0.07 | -0.20 | -0.14 | -0.12 | -0.11 | -0.12 | -0.08 | -0.15 | -0.17 | -0.17 |
VRDN News
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Alpha Tau Reports 100% Local Disease Control in Early Pancreatic Cancer Data as Program Gains Momentum (DRTS)
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market
Viridian eye disease drug benefits chronic patients in late-stage trial
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress